Page last updated: 2024-11-08

hippeastrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hippeastrine: isolated from Amaryllidaceae; structure given in first source; RN given refers to (5alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

hippeastrine : An indole alkaloid isolated from the Amaryllidaceae family and has been shown to exhibit cytotoxic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
AmaryllidaceaefamilyA family of herbaceous plants with bulbs or rhizomes in the order Asparagales.[MeSH]AmaryllidaceaeA family of herbaceous plants with bulbs or rhizomes in the order Asparagales.[MeSH]

Cross-References

ID SourceID
PubMed CID441594
CHEMBL ID457606
CHEBI ID5724
SCHEMBL ID4278126
MeSH IDM0168244

Synonyms (22)

Synonym
lycorenan-7-one, 5-hydroxy-1-methyl-9,10-(methylenebis(oxy))-, (5alpha)-
BRD-K71003802-001-02-9
hippeastrine hydrobromide
BSPBIO_000769
AB00513886
477-17-8
hippeastrine
C08528
nsc731436
nsc-731436
BPBIO1_000847
chebi:5724 ,
CHEMBL457606
HMS2097G11
(5s,5as,12bs,12cs)-5-hydroxy-1-methyl-2,3,5,5a,12b,12c-hexahydro[1,3]dioxolo[6,7]isochromeno[3,4-g]indol-7(1h)-one
SCHEMBL4278126
22352-41-6
DTXSID20197244
Q27106869
hippeastrine hbr
hippeastrine (hydrobromide)
(2s,3s,9s,10s)-9-hydroxy-4-methyl-11,16,18-trioxa-4-azapentacyclo[11.7.0.02,10.03,7.015,19]icosa-1(20),7,13,15(19)-tetraen-12-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
indole alkaloidAn alkaloid containing an indole skeleton.
delta-lactoneA lactone having a six-membered lactone ring.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
organic heteropentacyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID745326Antimalarial activity against chloroquine-sensitive Plasmodium falciparum F-32 Tanzania infected in blood assessed as decrease in parasitaemia after 48 hrs2013European journal of medicinal chemistry, May, Volume: 63Preparation and antimalarial activity of semisynthetic lycorenine derivatives.
AID335092Cytotoxicity against human Col2 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxicity of Hymenocallis expansa alkaloids.
AID335093Cytotoxicity against human HT cells after 3 days by sulforhodamine B assay1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxicity of Hymenocallis expansa alkaloids.
AID335097Cytotoxicity against human Lu1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxicity of Hymenocallis expansa alkaloids.
AID335091Cytotoxicity against human BC1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxicity of Hymenocallis expansa alkaloids.
AID335099Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxicity of Hymenocallis expansa alkaloids.
AID1578099Antiplasmodial activity against Trichomonas vaginalis assessed as reduction in plasmodium viability at 125 ug/ml relative to control2019Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID335096Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxicity of Hymenocallis expansa alkaloids.
AID335094Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxicity of Hymenocallis expansa alkaloids.
AID335095Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxicity of Hymenocallis expansa alkaloids.
AID335100Cytotoxicity against mouse P388 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxicity of Hymenocallis expansa alkaloids.
AID335098Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxicity of Hymenocallis expansa alkaloids.
AID335090Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxicity of Hymenocallis expansa alkaloids.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.20 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]